J&J nabs la­bel ex­pan­sion for Ste­lara in pe­di­atric pso­ri­at­ic arthri­tis

Near­ly a decade af­ter J&J’s Ste­lara was ap­proved to treat adults with pso­ri­at­ic arthri­tis, the phar­ma gi­ant is ex­pand­ing the la­bel to in­clude the small per­cent­age of chil­dren who suf­fer from the au­toim­mune dis­ease.

Reg­u­la­tors gave Ste­lara the green light on Mon­day for chil­dren ages six and old­er with ac­tive pso­ri­at­ic arthri­tis (PsA). The in­jectable will be ad­min­is­tered in two starter dos­es, fol­lowed by four shots per year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER